Bristol-Myers reviews $100m US media work

- The pharmaceuticals company, Bristol-Myers Squibb, has put its estimated $100 million (£60 million) US consumer prescription drug media business up for review.

- The pharmaceuticals company, Bristol-Myers Squibb, has put its estimated $100 million (£60 million) US consumer prescription drug media business up for review.

The account is currently handle by Western International Media, California. The business includes the Pravachol cholesterol-reduction brand, which makes up the bulk of the spending, but also includes Buspar anxiety and Zerit HIV treatments.





Topics

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus